Weir Matthew A, Fleet Jamie L, Vinden Chris, Shariff Salimah Z, Liu Kuan, Song Haoyuan, Jain Arsh K, Gandhi Sonja, Clark William F, Garg Amit X
1] Division of Nephrology, Department of Medicine, Western University, London, Ontario, Canada [2] Kidney Clinical Research Unit, Western University, London, Ontario, Canada.
Kidney Clinical Research Unit, Western University, London, Ontario, Canada.
Am J Gastroenterol. 2014 May;109(5):686-94. doi: 10.1038/ajg.2014.20. Epub 2014 Mar 4.
Bowel preparations are commonly prescribed drugs. Case reports and our clinical experience suggest that sodium picosulfate bowel preparations can precipitate severe hyponatremia in some older adults. At present, this risk is poorly quantified. We investigated the association between sodium picosulfate use and the risk of hyponatremia in older adults.
We conducted a population-based retrospective cohort study using six linked administrative databases in Ontario, Canada. All Ontario residents over the age of 65 years who filled an outpatient bowel preparation prescription before colonoscopy were eligible. We enrolled new users of either sodium picosulfate (n=99,237) or polyethylene glycol (n=48,595). The primary outcome was hospitalization with hyponatremia within 30 days of the bowel preparation assessed by database codes. The secondary outcomes were hospitalization with urgent head computed tomography (CT) (a proxy for acute central nervous system disturbance) and all-cause mortality.
The baseline characteristics of the two groups, including patient demographics, comorbid conditions, and concomitant medications, were nearly identical. Compared with polyethylene glycol, sodium picosulfate was associated with a higher risk of hospitalization with hyponatremia (absolute risk increase: 0.05%, 95% confidence interval (CI): 0.04-0.06%, relative risk (RR): 2.4, 95% CI: 1.5-3.9), but not hospitalization with urgent CT head (RR: 1.1, 95% CI: 0.7-1.4) or mortality (RR: 0.9, 95% CI: 0.7-1.3).
Sodium picosulfate bowel preparations lead to more hyponatremia than polyethylene glycol. There was no evidence of increased risk of acute neurologic symptoms or mortality. The absolute increase in risk of hospitalization with hyponatremia remains low but may be avoidable through appropriate fluid intake or preferential use of polyethylene glycol in some older adults.
肠道准备药物是常用处方药。病例报告及我们的临床经验表明,比沙可啶钠肠道准备药物可使部分老年人发生严重低钠血症。目前,这种风险的量化程度很低。我们研究了比沙可啶钠的使用与老年人低钠血症风险之间的关联。
我们利用加拿大安大略省六个相关的行政数据库进行了一项基于人群的回顾性队列研究。所有65岁以上在结肠镜检查前开具门诊肠道准备药物处方的安大略省居民均符合条件。我们纳入了比沙可啶钠新使用者(n = 99,237)或聚乙二醇新使用者(n = 48,595)。主要结局是通过数据库编码评估的肠道准备后30天内因低钠血症住院。次要结局是因紧急头部计算机断层扫描(CT)(急性中枢神经系统紊乱的替代指标)住院及全因死亡率。
两组的基线特征,包括患者人口统计学、合并症和伴随用药情况,几乎相同。与聚乙二醇相比,比沙可啶钠与因低钠血症住院的风险更高相关(绝对风险增加:0.05%,95%置信区间(CI):0.04 - 0.06%,相对风险(RR):2.4,95% CI:1.5 - 3.9),但与因紧急CT头部检查住院(RR:1.1,95% CI:0.7 - 1.4)或死亡率(RR:0.9,95% CI:0.7 - 1.3)无关。
比沙可啶钠肠道准备药物导致的低钠血症比聚乙二醇更多。没有证据表明急性神经症状或死亡率风险增加。因低钠血症住院风险的绝对增加仍然较低,但通过适当的液体摄入或在某些老年人中优先使用聚乙二醇可能是可以避免的。